Literature DB >> 25731635

Severe preeclampsia: what's new in intensive care?

Marc Leone1, Sharon Einav.   

Abstract

Preeclampsia remains an important cause of avoidable maternal morbidity and mortality. Publication of guidelines and monitoring adherence to life-saving therapies should be prioritized. Prediction of fluid responsiveness requires individual hemodynamic investigation. Future studies are required to determine the optimal early warning system and monitoring tools for providing early and non-invasive hemodynamic assessment.

Mesh:

Substances:

Year:  2015        PMID: 25731635     DOI: 10.1007/s00134-015-3701-9

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  19 in total

Review 1.  Focused review: spinal anesthesia in severe preeclampsia.

Authors:  Vanessa G Henke; Brian T Bateman; Lisa R Leffert
Journal:  Anesth Analg       Date:  2013-07-18       Impact factor: 5.108

2.  Ten years of confidential inquiries into maternal deaths in France, 1998-2007.

Authors:  Monica Saucedo; Catherine Deneux-Tharaux; Marie-Hélène Bouvier-Colle
Journal:  Obstet Gynecol       Date:  2013-10       Impact factor: 7.661

3.  ESC Guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC).

Authors:  Vera Regitz-Zagrosek; Carina Blomstrom Lundqvist; Claudio Borghi; Renata Cifkova; Rafael Ferreira; Jean-Michel Foidart; J Simon R Gibbs; Christa Gohlke-Baerwolf; Bulent Gorenek; Bernard Iung; Mike Kirby; Angela H E M Maas; Joao Morais; Petros Nihoyannopoulos; Petronella G Pieper; Patrizia Presbitero; Jolien W Roos-Hesselink; Maria Schaufelberger; Ute Seeland; Lucia Torracca
Journal:  Eur Heart J       Date:  2011-08-26       Impact factor: 29.983

4.  Prediction of fluid responsiveness in severe preeclamptic patients with oliguria.

Authors:  Clément Brun; Laurent Zieleskiewicz; Julien Textoris; Laurent Muller; Jean-Pierre Bellefleur; François Antonini; Maxime Tourret; Denis Ortega; Armand Vellin; Jean-Yves Lefrant; Léon Boubli; Florence Bretelle; Claude Martin; Marc Leone
Journal:  Intensive Care Med       Date:  2012-12-06       Impact factor: 17.440

5.  Lung ultrasound predicts interstitial syndrome and hemodynamic profile in parturients with severe preeclampsia.

Authors:  Laurent Zieleskiewicz; Claire Contargyris; Clément Brun; Maxime Touret; Armand Vellin; François Antonini; Laurent Muller; Florence Bretelle; Claude Martin; Marc Leone
Journal:  Anesthesiology       Date:  2014-04       Impact factor: 7.892

6.  A dose-response study of remifentanil for attenuation of the hypertensive response to laryngoscopy and tracheal intubation in severely preeclamptic women undergoing caesarean delivery under general anaesthesia.

Authors:  K Y Yoo; D H Kang; H Jeong; C W Jeong; Y Y Choi; J Lee
Journal:  Int J Obstet Anesth       Date:  2012-11-22       Impact factor: 2.603

7.  Pre-eclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health.

Authors:  E Abalos; C Cuesta; G Carroli; Z Qureshi; M Widmer; J P Vogel; J P Souza
Journal:  BJOG       Date:  2014-03       Impact factor: 6.531

Review 8.  Quantifying the fall in mortality associated with interventions related to hypertensive diseases of pregnancy.

Authors:  Carine Ronsmans; Oona Campbell
Journal:  BMC Public Health       Date:  2011-04-13       Impact factor: 3.295

Review 9.  Hypertensive disorders of pregnancy: a systematic review of international clinical practice guidelines.

Authors:  Tessa E R Gillon; Anouk Pels; Peter von Dadelszen; Karen MacDonell; Laura A Magee
Journal:  PLoS One       Date:  2014-12-01       Impact factor: 3.240

Review 10.  Global causes of maternal death: a WHO systematic analysis.

Authors:  Lale Say; Doris Chou; Alison Gemmill; Özge Tunçalp; Ann-Beth Moller; Jane Daniels; A Metin Gülmezoglu; Marleen Temmerman; Leontine Alkema
Journal:  Lancet Glob Health       Date:  2014-05-05       Impact factor: 26.763

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.